抄録
Linezolid (1) is an oxazolidinone antibiotic that is partially metabolized in vivo via ring cleavage of its morpholine moiety to mainly form two metabolites, PNU-142300 (2) and PNU-142586 (3). It is supposed that accumulation of 2 and 3 in patients with renal insufficiency may cause thrombocytopenia, one of the adverse effects of linezolid. However, the poor availability of 2 and 3 has hindered further investigation of the clinical significance of the accumulation of these metabolites. In this paper, we synthesized metabolites 2 and 3 via a common synthetic intermediate, 4; this will encourage further exploration of events related to these metabolites and lead to improved clinical use of linezolid.
本文言語 | English |
---|---|
ページ(範囲) | 194-199 |
ページ数 | 6 |
ジャーナル | Chemical and Pharmaceutical Bulletin |
巻 | 65 |
号 | 2 |
DOI | |
出版ステータス | Published - 2017 |
ASJC Scopus subject areas
- 化学 (全般)
- 創薬